LifeBay Enterprise Update: Ocumension Announces Phase III Clinical Trial Initiation for OT-802, a Novel Treatment for Presbyopia in Adults
Ocumension
Ophthalmic Drug Product Manufacturer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Click the blue text above to follow us
Innovation Keeps Growning
Recently, LifeBay EnterpriseOcumension TherapeuticsAnnouncementNew Drug OT- for the Treatment of Presbyopia in Adults802 Phase III Clinical Trial(The first subject was enrolled in a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase III clinical trial evaluating the efficacy and safety of OT-802 eye drops for the treatment of presbyopia in Chinese patients) at the Eye, Ear, Nose, and Throat Hospital of Fudan University.
Presbyopia is a common age-related decline in vision affecting nearly 2 billion people worldwide. It typically emerges after the age of 40, and while the current standard of care involves corrective lenses, this approach proves inconvenient for many individuals. Currently, there are no commercially available innovative pharmaceutical treatments for adult presbyopia in China. Furthermore, due to formulation limitations, existing internationally marketed drugs exhibit suboptimal efficacy and unfavorable side-effect profiles.
PilocarpineIt is a well-established ophthalmic therapeutic agent whose primary mechanism of action is miosis, thereby enhancing depth of field and improving near and intermediate visual acuity.
OT-802It is a product independently developed and globally owned by Ocumension Therapeutics. It utilizes the company's proprietaryProprietary Liquid-Liquid Dual-Chamber Technology, thereby ensuring the stability of pilocarpine eye drops under neutral conditions, which in turn improves their efficacy and side effect profile. Preclinical data indicate that OT-802 has a rapid onset of action, fewer adverse reactions, and favorable comfort, efficacy, and safety profiles.
Suzhou Ocumension Therapeutics Co., Ltd. was established on February 11, 2020, as a wholly-owned subsidiary of Ocumension Biopharmaceuticals (Hong Kong) Limited in China. The company is primarily engaged in licensed activities including pharmaceutical production (including sterile ophthalmic preparations), inspection and testing services, import and export agency for pharmaceuticals and medical devices, pharmaceutical wholesale and retail, as well as the production and operation of Class II and Class III medical devices. The manufacturing facility is strictly equipped with highly automated and intelligent advanced systems, currently possessing an annual production capacity of 455 million units of sterile ophthalmic preparations.
Source: Wuzhong Economic and Technological Development Zone Official Release
Suzhou Wuzhong Bio-Medical Industrial Park (LifeBay) is one of the first municipal-level bio-medicine industrial parks in Suzhou. It has been recognized as a Jiangsu Province Demonstration Base for Entrepreneurship and Innovation by Small and Micro Enterprises, and as a Jiangsu Province Characteristic Industrial Cluster for Small and Medium-sized Enterprises. In the latest 2024 national ranking of bio-medicine industrial park competitiveness in China, Suzhou Wuzhong Bio-Medical Industrial Park ranked 16th nationwide.
As the core of the Yangtze River Delta biomedical cluster, LifeBay is planned to develop over 1.5 million square meters of specialized facilities, establishing a full-chain ecosystem covering “R&D incubation – pilot scale-up acceleration – large-scale production.” Focusing on innovative drugs, high-end medical devices, biotechnology, digital health, and the broader health industry, and leveraging Wuzhong District’s robust foundation in intelligent manufacturing, LifeBay aims to accelerate the cultivation of the AI-pharmaceutical industry and promote the deep integration of AI with biopharmaceuticals. It strives to build a premier biomedical industrial hub centered on clinical value and driven by comprehensive, end-to-end development.
